loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Lomitapide Mesylate

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Lomitapide Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 171,409Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amryt Announces Positive Top Line Results from Ph3 Pediatric Trial of Lomitapide
    Amryt Announces Positive Top Line Results from Ph3 Pediatric Trial of Lomitapide

    05 Jan 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/01/05/2583508/0/en/Amryt-Announces-Positive-Top-Line-Results-from-Phase-3-Pediatric-Trial-of-Lomitapide-in-HoFH.html

    GLOBENEWSWIRE
    05 Jan 2023
    Share Share
    Coming out of Chapter 11, Aegerion jumps into welcome arms of Irish pharma
    Coming out of Chapter 11, Aegerion jumps into welcome arms of Irish pharma

    25 Sep 2019

    // Amber Tong ENDPTS

    https://endpts.com/coming-out-of-chapter-11-aegerion-jumps-into-welcome-arms-of-irish-pharma-with-big-plans-fresh-60m-for-its-drugs/

    Amber Tong ENDPTS
    25 Sep 2019
    Share Share
    Regeneron preps for 2020 filing for new cholesterol drug after trial success
    Regeneron preps for 2020 filing for new cholesterol drug after trial success

    18 Aug 2019

    // PHARMAPHORUM

    https://pharmaphorum.com/news/evinacumab-regeneron-cholesterol-drug-trial/

    PHARMAPHORUM
    18 Aug 2019
    Share Share
    Armed stellar if niche PhIII, Regeneron steers 'breakthrough' cholesterol drug
    Armed stellar if niche PhIII, Regeneron steers 'breakthrough' cholesterol drug

    14 Aug 2019

    // Amber Tong ENDPTS

    https://endpts.com/armed-with-stellar-if-niche-phiii-data-regeneron-steers-breakthrough-cholesterol-drug-to-post-pcsk9-waters/

    Amber Tong ENDPTS
    14 Aug 2019
    Share Share
    Amryt to expand rare disease portfolio with $311m Aegerion merger
    Amryt to expand rare disease portfolio with $311m Aegerion merger

    23 May 2019

    // Richard Staines PHARMAPHORUM

    https://pharmaphorum.com/news/amryt-to-expand-rare-disease-portfolio-with-311m-aegerion-merger/

    Richard Staines PHARMAPHORUM
    23 May 2019
    Share Share
    NHS England okays funding for cholesterol-lowering drug
    NHS England okays funding for cholesterol-lowering drug

    09 Jul 2018

    // Richard Staines PHARMAPHORUM

    https://pharmaphorum.com/news/nhs-england-okays-funding-for-cholesterol-lowering-drug-lojuxta/

    Richard Staines PHARMAPHORUM
    09 Jul 2018
    Share Share